BioCryst Pharmaceuticals Inc BCRX

BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

• Zacks Investment Research 18 sept

  4 Biotech Stocks to Watch as Potential Takeover Targets

  Biotech M&A activity has accelerated sharply in 2026, with deal value reaching $130 billion in H1 alone. Four biotech companies—Abivax, Iovance Biotherapeutics, Viking Therapeutics, and BioCryst Pharmaceuticals—are highlighted as potential acquisition targets due to their differentiated late-stage assets and strategic positioning in high-growth therapeutic areas including immunology, oncology, obesity, and rare diseases.

  

• GlobeNewswire Inc. 25 ago

  BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan

  Japan's Ministry of Health, Labor and Welfare approved ORLADEYO (berotralstat) granule formulation for prophylactic therapy in pediatric HAE patients aged 2 to <12 years. This marks the second regulatory approval for ORLADEYO in Japan and expands the company's market reach for its once-daily oral treatment. The approval is based on positive interim results from the APeX-P clinical trial showing the drug was well-tolerated with sustained reductions in monthly attack rates.

  

• GlobeNewswire Inc. 12 jun

  BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting

  BioCryst announced new clinical data and real-world evidence for ORLADEYO (berotralstat), its oral prophylactic therapy for hereditary angioedema (HAE), showing consistent reductions in HAE attack burden and healthcare utilization. The company also presented post hoc analysis from the Phase 1b/2 ALPHA-STAR study of investigational navenibart, a long-acting monoclonal antibody plasma kallikrein inhibitor, demonstrating consistent attack rate reductions across patient subgroups and supporting ongoing Phase 3 evaluation.